Discounted Cash Flow Rating

Strong Sell

Return on Equity Rating

Sell

Debt to Equity Rating

Neutral

Price to Earnings Rating

Strong Sell

Analyst Rating

Sell

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Standard Deviation

Strong Sell

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Neutral

Wall Street Data Solutions Rating

Sell

Ambrx Biopharma, Inc. Common Stock (AMAM)

Biological Products, (no Disgnostic Substances)

https://www.ambrx.com

Ambrx Biopharma Inc is a clinical-stage biologics company focused on discovering and developing a novel class of engineered precision biologics (EPBs) using its proprietary expanded genetic code technology platform that allows incorporating synthetic amino acids (SAAs) into proteins within living cells. Its product pipeline includes ARX788, ARX517, ARX305 among others.

10975 NORTH TORREY PINES ROAD
LA JOLLA, CA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

10/12/2023

Market Cap

1,772,097,600

Shares Outstanding

63,190,000

Weighted SO

63,189,227

Total Employees

N/A

Upcoming Earnings

04/04/2024

Similar Tickers

Beta

-2.3640

Last Div

0.0000

Range

6.55-28.15

Chg

0.0200

Avg Vol

1943941

Mkt Cap

1772097600

Exch

NYSE

Country

Phone

858 875 2400

DCF Diff

31.4287

DCF

-3.4287

Div Yield

0.0000

P/S

514.3970

EV Multiple

-22.2181

P/FV

7.1906

Div Yield %

0.0000

P/E

-25.1261

PEG

-0.6358

Payout

0.0000

Current Ratio

12.7993

Quick Ratio

12.4600

Cash Ratio

12.3310

DSO

249.7257

DIO

0.0000

Op Cycle

0.0000

DPO

0.0000

CCC

0.0000

Gross Margin

1.0000

Op Margin

-20.1733

Pretax Margin

-19.9518

Net Margin

-20.1366

Eff Tax Rate

-0.0093

ROA

-0.2555

ROE

-0.3498

ROCE

-0.2744

NI/EBT

1.0093

EBT/EBIT

0.9890

EBIT/Rev

-20.1733

Debt Ratio

0.0388

D/E

0.0434

LT Debt/Cap

0.0343

Total Debt/Cap

0.0416

Int Coverage

-14.2558

CF/Debt

-5.4829

Equity Multi

1.1200

Rec Turnover

1.4616

Pay Turnover

0.0000

Inv Turnover

0.0000

FA Turnover

0.2741

Asset Turnover

0.0127

OCF/Share

-0.9269

FCF/Share

-0.9450

Cash/Share

3.6186

OCF/Sales

-16.7480

FCF/OCF

1.0196

CF Coverage

-5.4829

ST Coverage

-30.1290

CapEx Coverage

-51.1498

Div&CapEx Cov

-51.1498

P/BV

7.1906

P/B

7.1906

P/S

514.3970

P/E

-25.1261

P/FCF

-30.1249

P/OCF

-30.2098

P/CF

-30.2098

PEG

-0.6358

P/S

514.3970

EV Multiple

-22.2181

P/FV

7.1906

DPS

0.0000

Latest Headlines (EST)

Benzinga Jan 09, 14:01 Assessing Ambrx Biopharma: Insights From 7 Financial Analysts AMAM GlobeNewswire Inc. Jan 08, 07:35 Ambrx Announces Sale to Johnson & Johnson AMAM MarketWatch Dec 28, 07:46 Here's a 'solid contrarian idea' for 2024, according to BTIG's Krinsky PSCH, XLV, ABBV, DHR, IQV, +32 more MarketWatch Dec 28, 06:34 Here's a 'solid contrarian idea' for 2024, according to BTIG's Krinsky PSCH, XLV, ABBV, DHR, IQV, +32 more GlobeNewswire Inc. Dec 14, 08:48 Ambrx to be Added to the NASDAQ Biotechnology Index (NBI) AMAM Benzinga Nov 14, 13:01 Analyst Ratings for Ambrx Biopharma AMAM

Revenue Product Segmentation

Year	Purchases	Sales	Total Bought	Total Sold

Transaction Date	Name	Type Of Owner	Price	Securities Owned	Securities Transacted	Security Name	Transaction Type

Less Than 3 Months

0.00 Shares Bought (0 %)

0.00 Shares Sold (0%)

3 - 6 Months

0.00 Shares Bought (0 %)

0.00 Shares Sold (0%)

6 - 9 Months

2.06M Shares Bought (97.63 %)

50.01K Shares Sold (2.37%)

9 - 12 Months

4.34M Shares Bought (100.00 %)

0.00 Shares Sold (0.00 %)

Investor Name	Investment Discretion	Type of Security	Shares Owned	Avg Price Paid	Market Value	Change In Market Value	Change In Market Value (%)	Ownership	Weight

Date	Investors Holding	Closed Positions	Increased Positions	Reduced Positions	New Positions	Total Invested	Put/Call Ratio	Total Calls	Total Puts

Owner	Shares Owned

	2020	2022	2023	2023	1970
Revenue	3.60M	▼ 1.16M	▲ 2.25M	▼ 53.00K	▼
Cost Of Revenue	0.00	0.00	0.00	0.00
Gross Profit	3.60M	▼ 1.16M	▲ 2.25M	▼ 53.00K	▼
Gross Profit Ratio	1.00	1.00	1.00	1.00	▼
Research And Development Expenses	5.25M	▲ 16.11M	▼ 10.27M	▲ 16.27M	▼
General And Administrative Expenses	1.88M	▲ 4.30M	▲ 5.59M	▲ 9.41M	▼
Selling And Marketing Expenses	37.50K	▲ 348.00K	▲ 681.50K	▼ 0.00
Selling General And Administrative Expenses	1.91M	▲ 4.65M	▲ 6.27M	▲ 9.41M	▼
Other Expenses	0.00	▲ 102.96M	▼ 42.93M	▼ 59.00K	▼
Operating Expenses	-9.49M	▼ -20.70M	▲ -15.94M	▲ 25.68M	▼
Cost And Expenses	-9.49M	▼ -20.70M	▲ -15.94M	▲ 25.68M	▼
Interest Income	0.00	0.00	▲ 555.50K	▲ 2.87M	▼
Interest Expense	-3.00K	▲ 1.66M	▲ 4.47M	▼ 0.00
Depreciation And Amortization	-483.50K	▼ -586.50K	▲ -124.00K	▲ 381.00K	▼
Ebitda	-3.05M	▼ -18.46M	▲ -8.79M	▼ -25.11M	▼
Ebitda Ratio	-0.85	▼ -15.89	▲ -3.92	▼ -100.00	▼
Operating Income	-3.54M	▼ -17.88M	▲ -8.67M	▼ -25.63M	▼
Operating Income Ratio	-0.98	▼ -15.39	▲ -3.86	▼ -483.51	▼
Total Other Income Expenses Net	-2.37M	▲ -1.66M	▼ -4.47M	▲ -81.00K	▼
Income Before Tax	-5.90M	▼ -19.53M	▲ -13.14M	▼ -22.84M	▼
Income Before Tax Ratio	-1.64	▼ -16.82	▲ -5.85	▼ -100.00	▼
Income Tax Expense	621.00K	▲ 1.66M	▼ 110.50K	▲ 148.00K	▼
Net Income	-5.55M	▼ -21.19M	▲ -13.25M	▼ -22.99M	▼
Net Income Ratio	-1.54	▼ -18.25	▲ -5.90	▼ -100.00	▼
Eps	-0.41	▼ -1.04	▲ -0.34	▼ -0.37	▼
Eps Diluted	-0.41	▼ -1.04	▲ -0.34	▼ -0.37	▼
Weighted Average Shs Out	13.61M	▲ 20.45M	▲ 38.62M	▲ 62.25M	▼
Weighted Average Shs Out Dil	13.61M	▲ 20.45M	▲ 38.62M	▲ 62.25M	▼